2021 Categorical Adjustment Index Measure Supplement

This supplement provides the details related to the adjusted measure set for the 2021 Categorical Adjustment Index (CAI).

CMS has updated the analyses examining the variability of the within-contract differences in performance between LIS/DE and non-LIS/DE beneficiaries for the candidate set of measures for informational purposes.

Figure 1 in the appendix depicts the within-contract LIS/DE and non-LIS/DE differences for the contracts that received a Star Rating in the 2020 Star Ratings. The figure first provides the variability of the within-contract differences for MA contracts, followed by the variability of PDPs. Figure 2 is provided to aid in the interpretation of the visuals. Tables 1 through 4 provide descriptive statistics of the within-contract differences that underlie the visuals in the Figure 1. Tables 1 and 3 provide the overall summary statistics for central tendency and dispersion for MA and PDP contracts, respectively. Tables 2 and 4 provide specific points of the distribution of the within-contract differences for MA and PDP contracts, respectively.

For the 2021 Star Ratings, the adjusted measures include the following: Adult BMI Assessment, Annual Flu Vaccine, Breast Cancer Screening, Colorectal Cancer Screening, Diabetes Care – Blood Sugar Controlled, Diabetes Care – Eye Exam, Diabetes Care – Kidney Disease Monitoring, Improving Bladder Control, Medication Reconciliation Post-Discharge, MTM Program Completion Rate for CMR, Monitoring Physical Activity, Osteoporosis Management in Women who had a Fracture, Reducing the Risk of Falling, Rheumatoid Arthritis Management, Medication Adherence for Diabetes Medications, Medication Adherence for Hypertension, Medication Adherence for Cholesterol, Statin Therapy for Patients with Cardiovascular Disease, and Statin Use in Persons with Diabetes.

Appendix

Figure 1: Variation across MA and PDP Contracts of the Within-Contract LIS/DE Differences





Figure 2: Interpretation of the Visual of the Variation across Contracts of the Within-Contract LIS/DE Differences*



^{*} The example is not based on 2021 results and thus, the values in the visual do not match the values in Figure 1 or Tables 1 and 2.

Table 1: Summary Statistics of the Within-Contract LIS/DE Differences for MA Contracts

| Measure Name | Mean | Median | Minimum | Maximum | Standard Deviation |
|---|----------|----------|----------|----------|--------------------|
| Breast Cancer Screening | -0.05846 | -0.05951 | -0.18684 | 0.11583 | 0.04082 |
| Colorectal Cancer Screening | -0.02533 | -0.02674 | -0.10901 | 0.08473 | 0.02667 |
| Annual Flu Vaccine | -0.04099 | -0.04009 | -0.08932 | -0.01516 | 0.01182 |
| Monitoring Physical Activity | -0.00717 | -0.00721 | -0.06700 | 0.06889 | 0.01981 |
| Adult BMI Assessment | 0.00391 | 0.00257 | -0.00306 | 0.05971 | 0.00488 |
| Osteoporosis Management in Women Who had a Fracture | -0.01870 | -0.01885 | -0.09452 | 0.04130 | 0.02181 |
| Diabetes Care – Eye Exam | -0.03068 | -0.02922 | -0.13388 | 0.07706 | 0.03371 |
| Diabetes Care – Kidney Disease Monitoring | 0.00107 | 0.00107 | -0.00741 | 0.01229 | 0.00201 |
| Diabetes Care – Blood Sugar Controlled | -0.04418 | -0.04245 | -0.09947 | -0.00781 | 0.01454 |
| Rheumatoid Arthritis Management | 0.01008 | 0.01020 | -0.04347 | 0.06212 | 0.01204 |
| Reducing the Risk of Falling | 0.11619 | 0.11639 | 0.08013 | 0.15362 | 0.01131 |
| Improving Bladder Control | -0.01046 | -0.01053 | -0.02521 | 0.00271 | 0.00415 |
| Medication Reconciliation Post-Discharge | -0.06657 | -0.07021 | -0.16648 | 0.07887 | 0.03498 |
| Statin Therapy for Patients with Cardiovascular Disease | 0.01195 | 0.01128 | -0.01507 | 0.04364 | 0.00722 |
| Part D Medication Adherence for Diabetes Medications | -0.01068 | -0.01115 | -0.04828 | 0.05762 | 0.01281 |
| Part D Medication Adherence for Hypertension | -0.03013 | -0.03046 | -0.08142 | 0.03351 | 0.01313 |
| Part D Medication Adherence for Cholesterol | -0.02335 | -0.02403 | -0.07650 | 0.05086 | 0.01533 |
| MTM Program Completion Rate for CMR | -0.02925 | -0.02828 | -0.13851 | 0.12035 | 0.02475 |
| Statin Use in Persons with Diabetes | 0.00526 | 0.00522 | -0.02913 | 0.04445 | 0.00861 |

Table 2: Within-Contract LIS/DE Difference Distribution Values for MA Contracts¹

| Measure Name | P2.5 | P5 | P10 | P25 | P50 | P75 | P90 | P95 | P97.5 |
|---|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| Breast Cancer Screening | -0.14309 | -0.12356 | -0.10975 | -0.08563 | -0.05951 | -0.03433 | -0.00943 | 0.00880 | 0.02202 |
| Colorectal Cancer Screening | -0.08663 | -0.06761 | -0.05510 | -0.03977 | -0.02674 | -0.01011 | 0.00360 | 0.01718 | 0.03557 |
| Annual Flu Vaccine | -0.07084 | -0.06223 | -0.05709 | -0.04747 | -0.04009 | -0.03337 | -0.02665 | -0.02355 | -0.02122 |
| Monitoring Physical Activity | -0.04858 | -0.04130 | -0.03063 | -0.01873 | -0.00721 | 0.00363 | 0.01725 | 0.02751 | 0.03425 |
| Adult BMI Assessment | 0.00087 | 0.00096 | 0.00127 | 0.00190 | 0.00257 | 0.00403 | 0.00697 | 0.01229 | 0.01541 |
| Osteoporosis Management in Women Who had a Fracture | -0.07397 | -0.05823 | -0.04137 | -0.02945 | -0.01885 | -0.00730 | 0.00817 | 0.02009 | 0.02929 |
| Diabetes Care – Eye Exam | -0.10306 | -0.08877 | -0.07612 | -0.04935 | -0.02922 | -0.01185 | 0.01181 | 0.02749 | 0.03551 |
| Diabetes Care – Kidney Disease Monitoring | -0.00321 | -0.0022 | -0.00108 | 0.00028 | 0.00107 | 0.00182 | 0.00310 | 0.00440 | 0.00556 |
| Diabetes Care – Blood Sugar Controlled | -0.07593 | -0.07259 | -0.06396 | -0.05272 | -0.04245 | -0.03375 | -0.02713 | -0.02372 | -0.02072 |
| Rheumatoid Arthritis Management | -0.01452 | -0.00962 | -0.00299 | 0.00511 | 0.01020 | 0.01600 | 0.02287 | 0.02786 | 0.03667 |
| Reducing the Risk of Falling | 0.09258 | 0.09881 | 0.10169 | 0.10981 | 0.11639 | 0.12292 | 0.12896 | 0.13404 | 0.13962 |
| Improving Bladder Control | -0.01866 | -0.01756 | -0.01590 | -0.01279 | -0.01053 | -0.00809 | -0.00556 | -0.00329 | -0.00162 |
| Medication Reconciliation Post-Discharge | -0.13619 | -0.12855 | -0.11114 | -0.08482 | -0.07021 | -0.04123 | -0.02237 | -0.01332 | -0.00548 |
| Statin Therapy for Patients with Cardiovascular Disease | -0.00208 | 0.00139 | 0.00353 | 0.00891 | 0.01128 | 0.01442 | 0.02109 | 0.02588 | 0.02960 |
| Part D Medication Adherence for Diabetes Medications | -0.03536 | -0.03216 | -0.02564 | -0.01748 | -0.01115 | -0.00645 | 0.00594 | 0.01254 | 0.01837 |
| Part D Medication Adherence for Hypertension | -0.05472 | -0.05141 | -0.04477 | -0.03706 | -0.03046 | -0.02401 | -0.01681 | -0.00994 | 0.00192 |
| Part D Medication Adherence for Cholesterol | -0.05076 | -0.04660 | -0.04210 | -0.03099 | -0.02403 | -0.01711 | -0.00660 | 0.00131 | 0.01161 |
| MTM Program Completion Rate for CMR | -0.08147 | -0.06813 | -0.05579 | -0.04106 | -0.02828 | -0.01691 | -0.00536 | 0.00896 | 0.02080 |
| Statin Use in Persons with Diabetes | -0.01301 | -0.00805 | -0.00493 | 0.00194 | 0.00522 | 0.00840 | 0.01604 | 0.01864 | 0.02470 |

¹ The values provided in the table correspond to the percentiles in the distribution of the variation across MA contracts of the within-contract LIS/DE differences depicted in Figure 1 for MA contracts.

Table 3: Summary Statistics of the Within-Contract LIS/DE Differences for PDPs

| Measure Name | Mean | Median | Minimum | Maximum | Standard Deviation |
|--|----------|----------|----------|----------|-----------------------|
| Part D Medication Adherence for Diabetes Medications | -0.03607 | -0.03211 | -0.13431 | 0.02714 | 0.02400 |
| Part D Medication Adherence for Hypertension | -0.05218 | -0.04736 | -0.13314 | -0.01536 | 0.02476 |
| Part D Medication Adherence for Cholesterol | -0.02984 | -0.02693 | -0.13585 | 0.02233 | 0.02850 |
| MTM Program Completion Rate for CMR | -0.10214 | -0.09092 | -0.34953 | 0.06363 | 0.08937 |
| Statin Use in Persons with Diabetes | -0.01994 | -0.02090 | -0.04853 | 0.00595 | 0.01201 |

Table 4: Within-Contract LIS/DE Difference Distribution Values for PDPs²

| Measure Name | P2.5 | P5 | P10 | P25 | P50 | P75 | P90 | P95 | P97.5 |
|--|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| Part D Medication Adherence for Diabetes Medications | -0.09750 | -0.07725 | -0.06142 | -0.04352 | -0.03211 | -0.02268 | -0.01361 | -0.00777 | -0.00176 |
| Part D Medication Adherence for Hypertension | -0.11439 | -0.10844 | -0.08881 | -0.06583 | -0.04736 | -0.03351 | -0.02655 | -0.02101 | -0.01873 |
| Part D Medication Adherence for Cholesterol | -0.09699 | -0.08057 | -0.06538 | -0.04239 | -0.02693 | -0.01037 | -0.00176 | 0.00938 | 0.01256 |
| MTM Program Completion Rate for CMR | -0.34302 | -0.24897 | -0.22442 | -0.15529 | -0.09092 | -0.03512 | -0.00308 | 0.01781 | 0.03712 |
| Statin Use in Persons with Diabetes | -0.04618 | -0.04314 | -0.03194 | -0.02505 | -0.02090 | -0.01408 | -0.00280 | 0.00457 | 0.00592 |

² The values provided in the table correspond to the percentiles in the distribution of the variation across PDP contracts of the within-contract LIS/DE differences depicted in Figure 1 for PDPs.